Evolva acquires Allylix for $61 million, acquisition trend continues

This week, Evolva acquired Allylix, which will now become a wholly owned subsidiary of Evolva. Evolva will acquire Allylix in exchange for 46 million Evolva shares, valued at $61 million. Cargill, Evolva’s stevia program partner, will invest $4 million in the company’s shares in support of this a...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Inbiose adds another €15 million to bring new HMOs to market

News Commentary | July 22, 2021

Inbiose received this funding in the form of a loan from the European Investment Bank (EIB), helping the company scale up production for other new HMOs beyond 2’‑fucosyllactose. In line with its commercialization plans, Inbiose recently submitted applications for FDA's regulatory approval covering ... Not part of subscription

Nature's Fynd set to construct new manufacturing facility in Chicago and launch products locally

News Commentary | November 11, 2021

The expansion follows $350 million Series C funding in July and will see the company construct a 200,000 ft2 facility in Chicago — adding 200 staff to its workforce for a total of 350 by 2023. Its recent launch of a cream cheese spread and sausage patties distinguishes it from most alternative ... Not part of subscription

ADM to strengthen its gut health portfolio by acquiring Deerland Probiotics & Enzymes

News Commentary | November 11, 2021

ADM has been keen on growing its gut health offerings, starting with the acquisition of Protexin in 2018. Over the past couple of years, the company has also expanded its existing product categories to accommodate new application areas. While the financial details of Deerland's acquisition are not ... To read more, click here.